TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Placebo-Controlled, Double-Blind, Randomized, Parallel Study Of The Efficacy And Safety Of Dapoxetine HCl In The Treatment Of Rapid Ejaculation
Brief Summary: The primary purpose of the study is to demonstrate that dapoxetine can prolong intravaginal ejaculatory latency time (IELT) compared with placebo in men with premature ejaculation (PE).


Options:
A: Arm Label: Dapoxetine + PDE5I; Type: EXPERIMENTAL; Interventions: Drug: Dapoxetine, Drug: PDE5I (phosphodiesterase-5 inhibitor) | Arm Label: Placebo + PDE5I; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: PDE5I (phosphodiesterase-5 inhibitor) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + PDE5I | Intervention Type: DRUG; Name: Dapoxetine; Assigned to Arm(s): Dapoxetine + PDE5I | Intervention Type: DRUG; Name: PDE5I (phosphodiesterase-5 inhibitor); Assigned to Arm(s): Dapoxetine + PDE5I, Placebo + PDE5I
B: Intervention Type: DRUG; Name: dapoxetine; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Dapoxetine; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Dapoxetine; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Correction of Hemoglobin and Outcomes In Renal Insufficiency
Brief Summary: The purpose of this study is to compare the outcomes of patients with chronic kidney disease (CKD) randomly assigned to 2 treatment groups, which differ only in their targeted hemoglobin levels. This study will test the primary hypothesis that the level of anemia correction with once weekly dosing of PROCRITÂ® (Epoetin alfa) in patients with chronic kidney disease will decrease mortality and cardiovascular morbidity.


Options:
A: Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): N/A
B: Arm Label: RO0503821 (1x/2 Weeks); Type: EXPERIMENTAL; Interventions: Drug: RO0503821 (1x/2 Weeks) | Arm Label: RO0503821 (1x/4 Weeks); Type: EXPERIMENTAL; Interventions: Drug: RO0503821 (1x/4 Weeks) | Arm Label: Epoetin (1-3x/Weeks); Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin alfa or beta | Intervention Type: DRUG; Name: Epoetin alfa or beta; Assigned to Arm(s): Epoetin (1-3x/Weeks) | Intervention Type: DRUG; Name: RO0503821 (1x/2 Weeks); Assigned to Arm(s): RO0503821 (1x/2 Weeks) | Intervention Type: DRUG; Name: RO0503821 (1x/4 Weeks); Assigned to Arm(s): RO0503821 (1x/4 Weeks)
C: Arm Label: Epoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin Alfa | Arm Label: Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): Epoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa
D: Arm Label: Darbepoetin alfa; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Correction of Hemoglobin and Outcomes In Renal Insufficiency
Brief Summary: The purpose of this study is to compare the outcomes of patients with chronic kidney disease (CKD) randomly assigned to 2 treatment groups, which differ only in their targeted hemoglobin levels. This study will test the primary hypothesis that the level of anemia correction with once weekly dosing of PROCRITÂ® (Epoetin alfa) in patients with chronic kidney disease will decrease mortality and cardiovascular morbidity.


Options:
A: Intervention Type: DRUG; Name: epoetin alfa; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): N/A
C: Arm Label: Early Epoetin Beta Therapy; Type: EXPERIMENTAL; Interventions: Drug: epoetin beta [NeoRecormon] | Arm Label: Late Epoetin Beta Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: epoetin beta [NeoRecormon] | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Early Epoetin Beta Therapy | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Late Epoetin Beta Therapy
D: Arm Label: TIW: Epoetin alfa 3 injections Weekly/Once Weekly; Type: EXPERIMENTAL; Interventions: Drug: Epoetin alfa 3 times weekly /once weekly | Arm Label: QW: Epoetin alfa once weekly; Type: EXPERIMENTAL; Interventions: Drug: Epoetin alfa once weekly | Arm Label: Q2W: Epoetin alfa once every two weeks; Type: EXPERIMENTAL; Interventions: Drug: Epoetin alfa once every two weeks | Intervention Type: DRUG; Name: Epoetin alfa 3 times weekly /once weekly; Assigned to Arm(s): TIW: Epoetin alfa 3 injections Weekly/Once Weekly | Intervention Type: DRUG; Name: Epoetin alfa once weekly; Assigned to Arm(s): QW: Epoetin alfa once weekly | Intervention Type: DRUG; Name: Epoetin alfa once every two weeks; Assigned to Arm(s): Q2W: Epoetin alfa once every two weeks

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Correction of Hemoglobin and Outcomes In Renal Insufficiency
Brief Summary: The purpose of this study is to compare the outcomes of patients with chronic kidney disease (CKD) randomly assigned to 2 treatment groups, which differ only in their targeted hemoglobin levels. This study will test the primary hypothesis that the level of anemia correction with once weekly dosing of PROCRITÂ® (Epoetin alfa) in patients with chronic kidney disease will decrease mortality and cardiovascular morbidity.


Options:
A: Arm Label: Darbepoetin alfa 6.75 mcg/kg Q4W; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin Alfa | Arm Label: Placebo Q4W; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Darbepoetin Alfa; Assigned to Arm(s): Darbepoetin alfa 6.75 mcg/kg Q4W | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Q4W
B: Intervention Type: DRUG; Name: epoetin alfa; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): N/A
D: Arm Label: Darbepoetin alfa; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Correction of Hemoglobin and Outcomes In Renal Insufficiency
Brief Summary: The purpose of this study is to compare the outcomes of patients with chronic kidney disease (CKD) randomly assigned to 2 treatment groups, which differ only in their targeted hemoglobin levels. This study will test the primary hypothesis that the level of anemia correction with once weekly dosing of PROCRITÂ® (Epoetin alfa) in patients with chronic kidney disease will decrease mortality and cardiovascular morbidity.


Options:
A: Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): N/A
B: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: darbepoetin alfa; Assigned to Arm(s): Active
C: Arm Label: RO0503821 (C.E.R.A.), 1x/4weeks; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): RO0503821 (C.E.R.A.), 1x/4weeks
D: Arm Label: Early Epoetin Beta Therapy; Type: EXPERIMENTAL; Interventions: Drug: epoetin beta [NeoRecormon] | Arm Label: Late Epoetin Beta Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: epoetin beta [NeoRecormon] | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Early Epoetin Beta Therapy | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Late Epoetin Beta Therapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Correction of Hemoglobin and Outcomes In Renal Insufficiency
Brief Summary: The purpose of this study is to compare the outcomes of patients with chronic kidney disease (CKD) randomly assigned to 2 treatment groups, which differ only in their targeted hemoglobin levels. This study will test the primary hypothesis that the level of anemia correction with once weekly dosing of PROCRITÂ® (Epoetin alfa) in patients with chronic kidney disease will decrease mortality and cardiovascular morbidity.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: epoetin beta [NeoRecormon] | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Intervention Type: DRUG; Name: darbepoetin alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): 1
B: Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): N/A
C: Arm Label: Early Epoetin Beta Therapy; Type: EXPERIMENTAL; Interventions: Drug: epoetin beta [NeoRecormon] | Arm Label: Late Epoetin Beta Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: epoetin beta [NeoRecormon] | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Early Epoetin Beta Therapy | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Late Epoetin Beta Therapy
D: Arm Label: Peginesatide 0.025 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: peginesatide | Arm Label: Peginesatide 0.04 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: peginesatide | Arm Label: Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: peginesatide; Assigned to Arm(s): Peginesatide 0.025 mg/kg | Intervention Type: DRUG; Name: peginesatide; Assigned to Arm(s): Peginesatide 0.04 mg/kg | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Omega-3 Fatty Acid Treatment of 174 Patients With Mild to Moderate Alzheimer's Disease (OmegAD): a Randomized Double-blind Trial
Brief Summary: Memory loss and difficulties with thinking associated with Alzheimer's disease (AD) may be due to a deficiency in the brain of a fatty acid named DHA. The aim of this trial is to see if dietary supplementation with a preparation, rich in DHA, will halt cognitive impairment in AD patients


Options:
A: Intervention Type: DRUG; Name: EPAX 1050TG; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: N/A; Interventions: Procedure: Magnetic Resonance Imaging (MRI), Procedure: Positron Emission Tomography (PET), Procedure: Lumbar Puncture (LP) | Arm Label: 2; Type: N/A; Interventions: Procedure: Magnetic Resonance Imaging (MRI), Procedure: Positron Emission Tomography (PET), Procedure: Lumbar Puncture (LP) | Arm Label: 3; Type: N/A; Interventions: Procedure: Magnetic Resonance Imaging (MRI), Procedure: Positron Emission Tomography (PET), Procedure: Lumbar Puncture (LP) | Intervention Type: PROCEDURE; Name: Magnetic Resonance Imaging (MRI); Assigned to Arm(s): 1, 2, 3 | Intervention Type: PROCEDURE; Name: Positron Emission Tomography (PET); Assigned to Arm(s): 1, 2, 3 | Intervention Type: PROCEDURE; Name: Lumbar Puncture (LP); Assigned to Arm(s): 1, 2, 3
C: Arm Label: 1.; Type: EXPERIMENTAL; Interventions: Drug: DHA (Docosahexaenoic Acid) | Arm Label: 2.; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: DHA (Docosahexaenoic Acid); Assigned to Arm(s): 1. | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2.
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: dl-alpha-tocopherol | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Memantine | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: dl-alpha-tocopherol, Drug: Memantine | Arm Label: Arm 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: dl-alpha-tocopherol; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: dl-alpha-tocopherol; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 4

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The HMO Research Network CERT: Acute Myocardial Infarction
Brief Summary: The primary goal of this study is to evaluate the effectiveness of direct-to-patient mailings designed to increase patient's adherence to prescribed beta-blockers following an acute myocardial infarction (AMI).

Prior to developing patient materials, focus groups were conducted with patient who had previously suffered an acute myocardial infarction (AMI) to identify the issues and information that patients felt were important to include in our materials as well as the best way to present the information. Additionally, patient materials were "pre-tested" with AMI patients to ensure that the materials were clear and easy to read and that the key messages were understood.


Options:
A: Arm Label: Beta-blocker adherence after an AMI; Type: EXPERIMENTAL; Interventions: Behavioral: Beta-blocker adherence after an AMI | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Beta-blocker adherence after an AMI; Assigned to Arm(s): Beta-blocker adherence after an AMI
B: Arm Label: Intervention Arm; Type: N/A; Interventions: N/A | Arm Label: Non-intervention - Usual Standard of Care; Type: N/A; Interventions: N/A
C: Arm Label: Active Screening; Type: OTHER; Interventions: Device: nucleic acid amplification of nasal swab; nasal swab culture | Arm Label: Passive Screening; Type: OTHER; Interventions: Other: Nasal swab culture | Intervention Type: DEVICE; Name: nucleic acid amplification of nasal swab; nasal swab culture; Assigned to Arm(s): Active Screening | Intervention Type: OTHER; Name: Nasal swab culture; Assigned to Arm(s): Passive Screening
D: Arm Label: Hand hygiene; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Hand hygiene plus gloving; Type: EXPERIMENTAL; Interventions: Other: Gloves | Intervention Type: OTHER; Name: Gloves; Assigned to Arm(s): Hand hygiene plus gloving

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The HMO Research Network CERT: Acute Myocardial Infarction
Brief Summary: The primary goal of this study is to evaluate the effectiveness of direct-to-patient mailings designed to increase patient's adherence to prescribed beta-blockers following an acute myocardial infarction (AMI).

Prior to developing patient materials, focus groups were conducted with patient who had previously suffered an acute myocardial infarction (AMI) to identify the issues and information that patients felt were important to include in our materials as well as the best way to present the information. Additionally, patient materials were "pre-tested" with AMI patients to ensure that the materials were clear and easy to read and that the key messages were understood.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Metoprolol controlled release (CR) | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Metoprolol controlled release (CR); Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
B: Arm Label: Beta blocker treatment; Type: EXPERIMENTAL; Interventions: Drug: Metoprolol Succinate, Drug: Bisoprolol, Drug: Carvedilol, Drug: Nebivolol | Arm Label: No beta blocker treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Metoprolol Succinate; Assigned to Arm(s): Beta blocker treatment | Intervention Type: DRUG; Name: Bisoprolol; Assigned to Arm(s): Beta blocker treatment | Intervention Type: DRUG; Name: Carvedilol; Assigned to Arm(s): Beta blocker treatment | Intervention Type: DRUG; Name: Nebivolol; Assigned to Arm(s): Beta blocker treatment
C: Arm Label: Beta-blocker adherence after an AMI; Type: EXPERIMENTAL; Interventions: Behavioral: Beta-blocker adherence after an AMI | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Beta-blocker adherence after an AMI; Assigned to Arm(s): Beta-blocker adherence after an AMI
D: Intervention Type: DRUG; Name: clopidogrel and metoprolol; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Double-blind Placebo-controlled Trial to Evaluate the Impact of Vitamin A on Maternal Mortality in Ghana
Brief Summary: Main objectives: To evaluate the impact of weekly vitamin A supplementation (VAS) to women of reproductive age (15-45 years) on maternal mortality in rural Ghana, and to compare this with the impact on overall mortality.

Hypotheses:

1. Weekly supplementation with vitamin A (7000 µg retinol equivalent \[RE\]) to reproductive age women will reduce maternal deaths by 33%.
2. This impact will be achieved by reductions in both pregnancy-related and non-pregnancy-related deaths.
3. There will be a reduction in non-maternal deaths, similar in size to that in maternal non-pregnancy related deaths.

Outcome measures: Maternal mortality rate, and overall mortality rate. Deaths will be identified through monthly demographic surveillance, and classified as maternal (pregnancy-related, non-pregnancy-related) or non-maternal using verbal autopsies.


Options:
A: Arm Label: Orange maize; Type: EXPERIMENTAL; Interventions: Other: Orange maize feeding | Arm Label: Blue vitamin A group; Type: ACTIVE_COMPARATOR; Interventions: Other: Vitamin A supplement | Arm Label: White; Type: PLACEBO_COMPARATOR; Interventions: Other: Oil only | Intervention Type: OTHER; Name: Orange maize feeding; Assigned to Arm(s): Orange maize | Intervention Type: OTHER; Name: Vitamin A supplement; Assigned to Arm(s): Blue vitamin A group | Intervention Type: OTHER; Name: Oil only; Assigned to Arm(s): White
B: Arm Label: a; Type: EXPERIMENTAL; Interventions: Drug: Glutamine | Arm Label: b; Type: EXPERIMENTAL; Interventions: Drug: Vitamin A, Drug: zinc | Arm Label: c; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin A, Drug: zinc | Arm Label: d; Type: PLACEBO_COMPARATOR; Interventions: Drug: glycine | Arm Label: e; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vitamin A, Drug: zinc | Arm Label: f; Type: EXPERIMENTAL; Interventions: Drug: Vitamin A, Drug: zinc | Intervention Type: DRUG; Name: Glutamine; Assigned to Arm(s): a | Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): b, c, e, f | Intervention Type: DRUG; Name: glycine; Assigned to Arm(s): d | Intervention Type: DRUG; Name: zinc; Assigned to Arm(s): b, c, e, f
C: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: vitamin A supplement; Type: ACTIVE_COMPARATOR; Interventions: Drug: vitamin A supplements | Intervention Type: DRUG; Name: vitamin A supplements; Assigned to Arm(s): vitamin A supplement | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
D: Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Double-blind Placebo-controlled Trial to Evaluate the Impact of Vitamin A on Maternal Mortality in Ghana
Brief Summary: Main objectives: To evaluate the impact of weekly vitamin A supplementation (VAS) to women of reproductive age (15-45 years) on maternal mortality in rural Ghana, and to compare this with the impact on overall mortality.

Hypotheses:

1. Weekly supplementation with vitamin A (7000 µg retinol equivalent \[RE\]) to reproductive age women will reduce maternal deaths by 33%.
2. This impact will be achieved by reductions in both pregnancy-related and non-pregnancy-related deaths.
3. There will be a reduction in non-maternal deaths, similar in size to that in maternal non-pregnancy related deaths.

Outcome measures: Maternal mortality rate, and overall mortality rate. Deaths will be identified through monthly demographic surveillance, and classified as maternal (pregnancy-related, non-pregnancy-related) or non-maternal using verbal autopsies.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin A or Beta-Carotene Supplements | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin A or Beta-Carotene Supplements | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin A or Beta-Carotene Supplements | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A or Beta-Carotene Supplements; Assigned to Arm(s): 1, 2, 3
B: Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A; Assigned to Arm(s): N/A
C: Arm Label: MMN; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multiple micronutrient supplements (MMN) | Arm Label: IFA; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: IFA | Intervention Type: DIETARY_SUPPLEMENT; Name: Multiple micronutrient supplements (MMN); Assigned to Arm(s): MMN | Intervention Type: DIETARY_SUPPLEMENT; Name: IFA; Assigned to Arm(s): IFA
D: Arm Label: Vitamin A; Type: N/A; Interventions: Dietary Supplement: Vitamin A alone | Arm Label: No Vitamin A; Type: N/A; Interventions: Dietary Supplement: Multivitamins excluding vitamin A, Dietary Supplement: multivitamins including vitamin A, Other: Placebo | Arm Label: Multivitamins; Type: N/A; Interventions: Dietary Supplement: Vitamin A alone, Dietary Supplement: Multivitamins excluding vitamin A, Dietary Supplement: multivitamins including vitamin A | Arm Label: No Multivitamins; Type: N/A; Interventions: Dietary Supplement: Vitamin A alone, Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A alone; Assigned to Arm(s): Multivitamins, No Multivitamins, Vitamin A | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamins excluding vitamin A; Assigned to Arm(s): Multivitamins, No Vitamin A | Intervention Type: DIETARY_SUPPLEMENT; Name: multivitamins including vitamin A; Assigned to Arm(s): Multivitamins, No Vitamin A | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): No Multivitamins, No Vitamin A

Answer: B